CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

I downgrade Pfizer to 'Strong Sell' as its high dividend yield fails to offset persistent share price weakness and lack of ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Dividend stocks are a smart way to navigate an uncertain market. Besides generating steady passive income, dividend-paying ...

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

Pfizer's Depo-Provera shot has been linked to brain tumors — and hundreds of women are suing the pharmaceutical giant over it ...